FDA accepts Mesoblast’s responses Biotech company Mesoblast has announced that the United States Food and Drug Administration (FDA) has accepted Mesoblast’s Biologics License Application (BLA) resubmission for Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). According to a statement, the FDA considers the resubmission to be a complete…
Our editorial series Towards 3% R&D – Turbocharging Australia’s Innovation Effort – requires a trained and inspired workforce. But how to achieve that? By Michael Edwards of Boeing Research and Technology. Enhancing performance, safety and efficiency of Boeing’s products and services are at the forefront of Boeing’s innovation teams’ minds when developing technological advancements for…
The federal government has pushed forward with plans to develop and field the MQ-28A Ghost Bat unmanned aerial vehicle (UAV) which is seen as a companion for manned Royal Australian Air Force planes. The government said it has secured hundreds of highly skilled jobs while driving industry innovation with the allocation of an additional $399…
Ten Australian manufacturers will share more than $3.6 million to develop cutting-edge defence capabilities and boost exports in the latest round of Defence grants. The payments include more than $800,000 to a New South Wales company producing hard armour for military personnel, $585,000 to a South Australian manufacturer to develop a large-scale environmental test chamber…
